Sales Up 12.3% Year-on-Year
Operating Profit Grows 50.7%

Celltrion Pharm announced on the 5th through an earnings disclosure that it posted annual sales of 536.4 billion won and operating profit of 56.1 billion won last year. Compared with the previous year, sales increased by 12.3% and operating profit by 50.7%, setting new all‑time highs for both sales and operating profit since the company was founded. Based on the fourth quarter of last year, sales came to approximately 154.4 billion won and operating profit to 13.7 billion won, up 13.9% and 31.1%, respectively, year-on-year, continuing a strong quarterly performance.


Celltrion Pharm cited the stable sales performance of its main products and the early entry of new products into the domestic market as the drivers behind this earnings growth. In particular, despite an increase in headcount and research and development expenses, the company achieved record-high results as cost improvements and maximum utilization of its PFS production facilities were maintained.

Celltrion Pharm Posts Record Results for Last Year... Sales 536.4 Billion Won, Operating Profit 56.1 Billion Won View original image

The chemical pharmaceuticals business division recorded total annual sales of 214.0 billion won. The liver agent Godex Capsule and the antihypertensive drug Dilatrend Tablet generated sales of 68.4 billion won and 57.4 billion won, respectively, up 2.4% and 14.3% from a year earlier. Products whose production has been internalized also continued their stable growth, among which diabetes treatments such as Nesina and Actos posted sales of 34.8 billion won, a 16.2% increase year-on-year.


In the biosimilar business division, the company achieved sales of 130.6 billion won, up 50.8% from the previous year, marking remarkable growth. Among these, three existing products already on the market - Remsima, Herzuma, and Truxima - together recorded sales of 79.7 billion won, and their steady upward trend drove overall earnings growth.


Vegzelma, an anticancer biosimilar used for metastatic colorectal cancer and non-small cell lung cancer, recorded sales of 12.7 billion won, up 235% from the previous year as prescriptions expanded at major tertiary general hospitals. Yuflyma, a treatment for autoimmune diseases, also settled into the market with sales of 7.7 billion won, an increase of 114.8%.


The growth trend of products newly launched in the domestic market last year also continued. Six new products - the autoimmune disease treatments Steqima and Aptozma, the ophthalmic disease treatment Eydenzelt, the allergic asthma treatment Omriclo, and the bone disease treatments Stoboclo and Osenbelt - together recorded sales of 30.5 billion won. This accounts for 23.3% of total biosimilar sales, and the competitiveness of these products along with an early market entry strategy supported this performance.


In the contract manufacturing division, demand increased across the entire biosimilar product portfolio, including Remsima SC (marketed in the United States under the brand name Zymfentra), the world’s only subcutaneous infliximab formulation, as well as Herzuma and Truxima. As a result, the PFS (Prefilled Syringe) production facilities maintained maximum utilization, and sales reached 139.6 billion won, up 2.80% from the previous year.


Following last year, Celltrion Pharm plans to continue driving earnings growth this year by further strengthening product competitiveness and keeping contract manufacturing utilization at the maximum level. In particular, the company intends to boost sales by expanding the market influence of newly launched biosimilar product lines, while also focusing on improving profitability in chemical pharmaceuticals by actively leveraging product groups such as Nesina, Actos, and Idalbi, for which production internalization has been completed.



A Celltrion Pharm official said, "Last year, we surpassed 500 billion won in sales for the first time in our history and achieved more than 50% year-on-year growth in operating profit, as external growth coincided with improvements in our cost and cost-of-goods structures," adding, "This year as well, we will maintain a high-growth trajectory while strengthening the competitiveness of our key products and pursuing stable, profitability-centered growth."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing